Resolution Health launches women’s health campaign
COLUMBIA, Md. The personal health care guidance company Resolution Health today announced the launch of their Women’s Health and Wellness Action Campaign. The campaign is a member outreach program that is designed to help increase the prevention and early detection of breast and cervical cancers in women.
Resolution Health’s comprehensive program begins with claims analysis to identify health plan members who have not undergone recommended mammogram or cervical cancer screenings. The Action Campaign reaches out to members on behalf of their health plan using phone-based, speech-enabled technology provided by Eliza Corp. These interactive calls engage the member in conversation about the importance of preventive cancer screenings and assess and address a member’s planned behavior regarding these screenings – including any potential barriers to have the tests. Based upon a member’s spoken responses, education and support follow-up is offered.
These member responses trigger a personalized follow-up mailing, providing actionable information on the importance of these screenings and addressing personal barriers to healthy behavior identified during the phone call. Depending upon a health plan’s benefit design, the mailing may also include a gift card incentive offer to reward members who complete the recommended procedures.
ImClone to pay $17.5 million to Abbott in Erbitux settlement
BOSTON ImClone Systems, manufacturer of the cancer drug Erbitux, has agreed to pay Abbott Laboratories $17.5 million to end a patent-infringement lawsuit over the medicine, according to Bloomberg.
The companies said in an Aug. 4 notice to U.S. District Judge Richard Stearns in Boston that they had reached a “confidential settlement.” Stearns put the case on hold so the companies can finish the paperwork on the agreement.
Abbott sued ImClone last year, claiming its patented method for creating antibodies is infringed by Erbitux. In May, ImClone filed a lawsuit accusing Abbott of withholding information that could have been used by ImClone to defend itself against a patent suit by Repligen. ImClone paid $65 million to end that case.
“We have reached an agreement in principle that would conclude all outstanding litigation with ImClone,” said Abbott spokesman Scott Stoffel.
FDA warns about muscle damage from drug combo
WASHINGTON Combining some heart drugs could cause muscular damage, Reuters reported the Food and Drug Administration as warning.
The FDA said it had received reports of the muscle injury rhabdomyolysis, which can cause kidney failure or death, related to combining the cholesterol drug simvastatin and the arrythmia drug amiodarone. The agency issued a warning about the risks of combining the drugs in 2002.
All statin drugs have the risk of causing rhabdomyolysis, but the risk becomes greater when simvastatin is combined with amiodarone.
Simvastatin is the active ingredient in Merck’s Simcor and Abbott Laboratories’ Zocor, as well as an ingredient in Merck’s and Schering-Plough’s Vytorin. Amiodarone is the active ingredient in Wyeth’s Cordarone and Upsher-Smith’s Pacerone.